Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease Portfolio of Oral Selective α4β7 Inhibitors Acquired from EA Pharma, Eisai’s GI Subsidiary Phase 2 Clinical Program in Ulcerative Colitis to Start in First Half of 2025 with Lead Asset Seasoned...

Worldwide License Agreement for EA1080, Oral Selective α4β7 Integrin Antagonist, Signed between EA Pharma and Ensho Therapeutics CHUO-KU, TOKYO and MORRIS PLAINS, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- EA Pharma Co., Ltd. (President, Hidenori Yabune; “EA Pharma”) and Ensho Therapeutics, Inc. (Founder, President and Chief...